Physician profile
Ajitesh Rai
NPI 1205883097
$7,921.66
in general payments reported to CMS, 2019-2025
56 companies · $572 in 2025
The $572 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,198 · 2020: $937 · 2021: $766 · 2022: $1,056 · 2023: $1,098 · 2024: $1,296 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,898 · Education: $67.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,898.17 |
| Education | $67.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $921.02 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $695.34 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $671.59 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $538.20 | 2019-2021 | |
| Ucb, INC. | $467.63 | 2019-2025 | Briviact, Rystiggo |
| Allergan, INC. | $362.95 | 2019-2020 | |
| Harmony Biosciences LLC | $284.75 | 2020-2025 | Wakix |
| Mdd US Operations, LLC | $268.95 | 2019 | |
| Lilly USA, LLC | $259.12 | 2019-2025 | Emgality, Zepbound, Kisunla |
| Sunovion Pharmaceuticals INC. | $256.02 | 2019-2022 | |
| Inspire Medical Systems, INC. | $222.79 | 2023-2025 | Inspire |
| Resmed Corp | $215.06 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $180.10 | 2019-2022 | |
| Amgen INC. | $174.80 | 2019-2022 | |
| Axsome Therapeutics, INC. | $171.52 | 2023-2025 | Sunosi |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajitesh Rai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.